Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus OMNIPAQUE 140.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus OMNIPAQUE 140.
CHOLOGRAFIN MEGLUMINE vs OMNIPAQUE 140
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
Radiopaque contrast agent that attenuates X-rays due to iodine content, enhancing vascular and tissue visualization.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
Intravascular: 50-200 mL (containing 7.0-28.0 g iodine) per procedure, administered intravenously as a bolus or infusion; dose depends on imaging modality and body region. Intrathecal: 6-15 mL (containing 0.84-2.1 g iodine) administered via lumbar puncture for myelography.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
Terminal elimination half-life: 1–2 hours; prolonged in renal impairment (up to 30–40 hours in severe dysfunction).
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent